← Back to Search

eHealth Cancer Genetic Counseling for Cancer (eReach Trial)

N/A

Recruiting

Research Sponsored by Abramson Cancer Center at Penn Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18 years of age or older

A personal history of one or more of the following: metastatic breast cancer, advanced ovarian cancer (Stage III-IV), metastatic pancreatic cancer, metastatic prostate cancer, Naive to previous cancer germline genetic testing

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline - within 7 days of visit 2

Awards & highlights

eReach Trial Summary

This trial will compare web-based eHealth cancer counseling to the standard of care to see if it is equally or more effective.

Who is the study for?

This trial is for adults who speak English and have certain advanced cancers (metastatic breast, ovarian stages III-IV, pancreatic, or prostate cancer) and haven't had genetic testing for cancer before. It's not suitable for those with hearing/vision/speech issues or uncontrolled mental conditions that affect understanding of the study.Check my eligibility

What is being tested?

The study tests if web-based eHealth delivery of genetic counseling before and after testing can match or surpass standard in-person care in terms of patients' knowledge and emotional well-being.See study design

What are the potential side effects?

Since this trial involves educational interventions rather than medications, traditional side effects are not expected. However, participants may experience a range of emotions as they learn about their genetic risks.

eReach Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have had advanced cancer (breast, ovarian, pancreatic, prostate) and haven't had genetic testing for it.

eReach Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline - within 7 days of visit 2

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline - within 7 days of visit 2

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline - within 7 days of visit 2 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Anxiety

Change in Knowledge

Secondary outcome measures

Change in Cancer Specific Distress

Change in Depression

Change in Health Behaviors

+3 more

eReach Trial Design

4Treatment groups

Experimental Treatment

Group I: ARM DExperimental Treatment2 Interventions

Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention. Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention.

Group II: ARM CExperimental Treatment2 Interventions

Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention. Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing).

Group III: ARM BExperimental Treatment2 Interventions

Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing). Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention.

Group IV: ARM AExperimental Treatment1 Intervention

Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing). Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing).

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Abramson Cancer Center at Penn MedicineLead Sponsor

387 Previous Clinical Trials

145,104 Total Patients Enrolled

Basser Center for BRCAUNKNOWN

1 Previous Clinical Trials

61 Total Patients Enrolled

Fox Chase Cancer CenterOTHER

227 Previous Clinical Trials

36,978 Total Patients Enrolled

Media Library

Pre-Test Intervention Clinical Trial Eligibility Overview. Trial Name: NCT04353973 — N/A

Cancer Research Study Groups: ARM B, ARM C, ARM A, ARM D

Cancer Clinical Trial 2023: Pre-Test Intervention Highlights & Side Effects. Trial Name: NCT04353973 — N/A

Pre-Test Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT04353973 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals currently being enrolled into this experiment?

"Affirmative. The clinicaltrials.gov website confirms that this venture is currently seeking volunteers, with the original posting date being August 17th 2020 and the most recent update being October 18th 2021. 560 people are hoped to be recruited from one site in total."

Answered by AI

How many human subjects are actively participating in this experiment?

"Affirmative, the clinicaltrials.gov record indicates that recruitment for this trial is still underway. It was first published on August 17th 2020 and most recently updated on October 18th 2021. 560 individuals will be required from one site to complete the study's objectives."

Answered by AI

What is the ultimate purpose of this experiment?

"The aim of this study, which is to be studied over the span of approximately one week from its starting point, will measure Change in Knowledge. Secondary evaluations include Frequency of Uptake of Testing (Yes/No), Change in Health Behaviors (Yes/No), and Provider Time (minutes)."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

2020. "Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04353973.

All > Hereditary Angioedema